Feline arthritis management in 2026 represents a significant welfare advance with Solensia and improved diagnosis transforming outcomes for affected cats.
2026 represents a genuine breakthrough year for feline arthritis welfare. The wide availability of Solensia provides effective monthly pain management for cats who previously had no good long-term options. The welfare gains for arthritic cats receiving Solensia - resumed grooming, improved mobility, return to social behaviour - are visible and striking to owners and vets. These gains represent real improvements in quality of life for millions of cats who were previously untreated or inadequately managed.